Diabetes lab
61 – 70 of 117
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Effect of liraglutide on anthropometric measurements, sagittal abdominal diameter and adiponectin levels in people with type 2 diabetes treated with multiple daily insulin injections: evaluations from a randomized trial (MDI-liraglutide study 5).
(
- Contribution to journal › Article
-
Mark
Obstetric and perinatal outcomes in pregnancies complicated by diabetes, and control pregnancies, in Kronoberg, Sweden
(
- Contribution to journal › Article
-
Mark
Strong association between vibration perception thresholds at low frequencies (4 and 8 Hz), neuropathic symptoms and diabetic foot ulcers
(
- Contribution to journal › Article
-
Mark
Lower HDL-cholesterol, a known marker of cardiovascular risk, was associated with depression in type 1 diabetes : A cross sectional study
(
- Contribution to journal › Article
-
Mark
Response to Letter to the Editor: "Suppressed ACTH Is Frequently Unrelated to Autonomous Cortisol Secretion in Patients With Adrenal Incidentalomas"
(
- Contribution to journal › Letter
-
Mark
Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections
(
- Contribution to journal › Article
-
Mark
Midnight salivary cortisol secretion and the use of antidepressants were associated with abdominal obesity in women with type 1 diabetes : A cross sectional study
(
- Contribution to journal › Article
-
Mark
Female sex, high soluble CD163, and low HDL-cholesterol were associated with high galectin-3 binding protein in type 1 diabetes
(
- Contribution to journal › Article
-
Mark
Midnight salivary cortisol secretion associated with high systolic blood pressure in type 1 diabetes
(
- Contribution to journal › Article
- 2018
-
Mark
Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
(
- Contribution to journal › Article